Log in

Company updateBusiness Standard

Biocon gets EU nod for Pebrilzo breast cancer drug

Positive+405 sources

GreyOak summary

Biocon Limited received marketing authorization from the European Commission for Pebrilzo, a pertuzumab biosimilar, to treat HER2-positive breast cancer. This approval makes it the first biosimilar under the EMA's new tailored clinical approach. The drug is now approved in both the US and EU, marking a significant milestone for the company's global oncology portfolio.

What it affects

  • BioconBIOCONPositive +40

    Received EU marketing authorization for Pebrilzo.Rolling sentiment Positive +18

Source

Read the original at Business Standard

More Biocon news

All Biocon news →

We use cookies

Essential cookies keep GreyOak secure and functional. Optional cookies help improve your experience and platform performance. You can update your preferences anytime.

Cookie Policy